(3S)-3-hydroxy-4-O-triphenylmethyloxybutanoic acid | 113240-54-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (3S)-3-hydroxy-4-O-triphenylmethyloxybutanoic acid
• 英文别名: (S)-3-Hydroxy-4-(triphenylmethoxy)butanoic acid；(3S)-3-Hydroxy-4-(triphenylmethoxy)butanoic acid；(3S)-3-hydroxy-4-trityloxybutanoic acid
• CAS: 113240-54-3
• 化学式: C₂₃H₂₂O₄
• 分子量: 362.425
• InChiKey: UHQWPLZQOQXPFS-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3S)-3-hydroxy-4-O-triphenylmethyloxybutanoic acid 在 三乙胺 、 氯甲酸异丁酯 、 sodium azide 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 反应 4.0h， 以30%的产率得到(5S)-5-(triphenylmethyloxymethyl)oxazolidin-2-one
  参考文献：
  名称：

  Synthesis of homochiral tetrahydropteridines

  摘要：

  A synthesis of protected homochiral tetrahydropteridines from (2S)-malic acid has been developed. This presents methodology for the synthesis of reduced pteridine coenzymes and pharmaceuticals. (C) 2014 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tet.2014.06.048
• 作为产物：
  描述：

  ethyl (3S)-3-hydroxy-4-O-triphenylmethyloxybutanoate 在 sodium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 36.0h， 以93%的产率得到(3S)-3-hydroxy-4-O-triphenylmethyloxybutanoic acid
  参考文献：
  名称：

  Synthesis of homochiral tetrahydropteridines

  摘要：

  A synthesis of protected homochiral tetrahydropteridines from (2S)-malic acid has been developed. This presents methodology for the synthesis of reduced pteridine coenzymes and pharmaceuticals. (C) 2014 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tet.2014.06.048

文献信息

• Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
  申请人：SANDOZ AG

  公开号：EP0367895A1

  公开（公告）日：1990-05-16

  Compounds of formula I wherein R¹, R², Q, X and Y have various significances, in free acid form, or in the form of an ester or δ-lactone thereof, or in salt form as appropriate, are described. They are indicated for use as hypolipoproteinemic and anti-atherosclerotic agents. They may be obtained by reduction, hydrolysis, deprotection or oxidation of appropriate starting compounds, and variously interconverted by e.g. hydrolysis, salt formation, esterification and/or lactonisation.

  式I中的化合物，其中R¹、R²、Q、X和Y具有不同的含义，在游离酸形式中，或者以其酯或δ-内酯的形式，或者以盐的形式描述。它们被指定用作降低脂蛋白和抗动脉粥样硬化药物。它们可以通过还原、水解、去保护或氧化适当的起始化合物获得，并通过水解、盐形成、酯化和/或内酯化等方法进行各种互变。
• Processes for the synthesis of diprotected
  申请人：Sandoz Pharm. Corp.

  公开号：US04870199A1

  公开（公告）日：1989-09-26

  Process for the synthesis of compounds of the formula ##STR1## in R[R*,S*] enantiomeric form, wherein each P.sub.1 is independently an hydroxy group-protecting group, and R.sub.2z is C.sub.1-4 alkyl, benzyl or allyl, comprising, as a key step when R.sub.2z is R.sub.2x, the reaction of the compound of the formula ##STR2## in (S) enantiomeric form with a compound of the formula Mg.sup. .circle.+2 (.sup..crclbar. OOC--CH.sub.2 --COOR.sub.2x).sub.2 to obtain a compound of the formula ##STR3## in (S) enantiomeric form, and, as a key step when R.sub.2z is R.sub.2y, the reaction of a compound of the formula ##STR4## in (S) enantioimeric form with a compound of the formula Li.sup..sym..crclbar. CH.sub.2 --COOR.sub.2y to obtain a compound of the formula ##STR5## in (S) enantiomeric form, wherein R.sub.2x is primary or secondary C.sub.1-4 alkyl, benzyl or allyl, R.sub.2y is C.sub.1-4 alkyl not containing an asymmetric carbon atom, and R.sub.3 ' is methyl or ethyl, processes for the synthesis of compounds of the formula ##STR6## comprising reacting a compound of the formula ##STR7## with the reaction product of a strong base and a compound of the formula ##STR8## optionally followed by, when R.sub.2z is allyl, cleavage of the allyl and P.sub.1 groups to obtain the corresponding compound of the formula ##STR9## wherein each R.sub.7 is methyl or ethyl, R is as defined in the specification, and each P.sub.1 independently and R.sub.2z are as defined above, and the compounds of the formula ##STR10## wherein R and each R.sub.7 are as defined above.

  合成具有以下结构的化合物的过程##STR1##以R[R*,S*]对映体形式存在，其中每个P.sub.1独立地是一个羟基保护基团，而R.sub.2z是C.sub.1-4烷基，苄基或烯丙基，包括作为关键步骤的情况，当R.sub.2z是R.sub.2x时，将具有以下结构的化合物##STR2##以(S)对映体形式与具有以下结构的化合物发生反应 Mg.sup. .circle.+2 (.sup..crclbar. OOC--CH.sub.2 --COOR.sub.2x).sub.2 以获得具有以下结构的化合物##STR3##以(S)对映体形式，并且作为关键步骤的情况，当R.sub.2z是R.sub.2y时，将具有以下结构的化合物##STR4##以(S)对映异构体形式与具有以下结构的化合物反应 Li.sup..sym..crclbar. CH.sub.2 --COOR.sub.2y 以获得具有以下结构的化合物##STR5##以(S)对映体形式，其中R.sub.2x是初级或次级C.sub.1-4烷基，苄基或烯丙基，R.sub.2y是不含手性碳原子的C.sub.1-4烷基，而R.sub.3 '是甲基或乙基，合成具有以下结构的化合物的过程##STR6##包括将具有以下结构的化合物##STR7##与强碱和具有以下结构的化合物的反应产物进行反应##STR8##，随后可选地，当R.sub.2z是烯丙基时，裂解烯丙基和P.sub.1基团以获得相应的具有以下结构的化合物##STR9##其中每个R.sub.7是甲基或乙基，R如规范中定义的那样，每个P.sub.1独立地和R.sub.2z如上所述定义，并且具有以下结构的化合物##STR10##其中R和每个R.sub.7如上所定义。
• Process for the preparation of oxazolidinones and method of use thereof
  申请人：Hollingsworth I. Rawle

  公开号：US20070265451A1

  公开（公告）日：2007-11-15

  A process for preparing N-(substituted)-C-(substituted methyl)-oxazolidinones, C-(substituted methyl)-oxazolidinones, and N-(substituted)-C-(substituted methyl)-oxazolidinones, preferably chiral, from optically active C-(protected oxymethyl)-oxazolidinones is described. The process can be used to produce combinatorial libraries of the above substituted oxazolidinones in a two or three step reaction comprising a plurality of reagents differing in numbers of carbons or particular substituted oxazolidinones. A number of substituted oxazolidinones produced using the above process have been discovered to have antimicrobial activity.

  本文介绍了一种从光学活性的C-（保护的氧甲基）-噁唑烷酮制备N-（取代）-C-（取代甲基）-噁唑烷酮、C-（取代甲基）-噁唑烷酮和N-（取代）-C-（取代甲基）-噁唑烷酮的方法，其中优选手性化合物。该方法可用于在包含多种碳数或特定取代噁唑烷酮的多种试剂的两步或三步反应中产生上述取代噁唑烷酮的组合库。使用上述方法生产的许多取代噁唑烷酮已被发现具有抗微生物活性。
• PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF
  申请人：Hollingsworth Rawle I.

  公开号：US20080146458A1

  公开（公告）日：2008-06-19

  Substituted oxazolidinone of the formula: wherein R 2 is alkyl selected from the group consisting of methyl, ethyl, and isopropyl moieties, are described. The compounds are antibacterial.

  描述了以下化学式的氧杂环丙酮类替代物：其中R2是选择自甲基，乙基和异丙基基团的烷基。这些化合物具有抗菌作用。
• 5-Substituted 1H-pyrazolo[3,4-b]pyridine derivatives, their preparation and pharmaceutical compositions containing them
  申请人：SANDOZ AG

  公开号：EP0327500A2

  公开（公告）日：1989-08-09

  Compounds of the formula wherein the substituents have various significances are described, together with processes for their synthesis and intermediates, pharmaceutical compositions comprising such compounds and the use of such compounds for inhibiting cholesterol biosynthesis and lowering the blood cholesterol level and, therefore, their use in the treatment of hyperlipoproteinemia and atherosclerosis.

  描述了式 其中的取代基具有各种意义，本文介绍了这些化合物及其合成工艺和中间体、包含这些化合物的药物组合物，以及这些化合物在抑制胆固醇生物合成和降低血液胆固醇水平方面的用途，因此也介绍了这些化合物在治疗高脂蛋白血症和动脉粥样硬化方面的用途。